Abbott Laboratories stock (US0028241000): shares rebound after earnings and guidance update

Abbott Laboratories stock has attracted renewed interest from US investors after the healthcare group reported higher first-quarter 2026 sales and earnings, raised its full-year outlook and confirmed a quarterly dividend, while the share price recovered modestly from recent lows, according to reports from Zacks on April 17, 2026 and MarketBeat on May 12, 2026.Zacks as of 04/17/2026MarketBeat as of 05/12/2026

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

According to Zacks, Abbott reported first-quarter 2026 worldwide sales of about $11.16 billion, up 7.8% year over year on a reported basis, with adjusted diluted earnings per share of $1.15, an increase of roughly 6% versus the prior-year period and ahead of analyst expectations.Zacks as of 04/17/2026

Following the earnings release, MarketBeat reported that Abbott shares rose about 2.1% on May 12, 2026, closing at around $84.34 after trading as high as approximately $85.10, on trading volume above the recent average, reflecting a modest rebound from 52-week lows.MarketBeat as of 05/12/2026

Zacks noted that the company completed a roughly $21 billion acquisition of Exact Sciences’ cancer diagnostics operations around the time of the quarter, expanding Abbott’s presence in oncology testing and potentially adding new long-term growth drivers to its diagnostics segment.Zacks as of 04/17/2026

In addition, MarketBeat highlighted that Abbott reaffirmed a quarterly cash dividend of $0.63 per share, payable to stockholders of record as of April 15, 2026, which underscores the company’s continuing focus on shareholder returns through regular income distributions.MarketBeat as of 05/12/2026

According to MarketBeat, the company also provided updated guidance for 2026, forecasting full-year adjusted EPS in a range of approximately $5.38 to $5.58 and second-quarter 2026 adjusted EPS between about $1.25 and $1.31, giving investors clearer visibility on expected profitability for the rest of the year.MarketBeat as of 05/12/2026

At the same time, sentiment around Abbott has been affected by legal and regulatory risks related to its infant formula business, with Simply Wall St reporting that a securities class action lawsuit alleges the company concealed health and safety violations at a facility, adding to pressure from a recently upheld $495 million verdict linked to baby formula operations.Simply Wall St as of 05/10/2026

Simply Wall St added that Abbott shares were recently about $84.35, down roughly 3.2% over the prior week and about 15.9% over the prior month, with the stock also lower over longer horizons, pointing to a period of underperformance despite the company’s diversified healthcare portfolio.Simply Wall St as of 05/10/2026

Abbott Laboratories: core business model

Abbott Laboratories is a diversified healthcare company with operations spanning medical devices, diagnostics, nutrition and established pharmaceuticals, aiming to generate recurring revenue from products used in hospitals, clinics and consumer health settings across many geographies.

In medical devices, Abbott offers cardiovascular, rhythm management, heart failure, neuromodulation and diabetes care products, including implantable devices, monitoring systems and glucose management technologies used by physicians and patients worldwide.

According to Zacks, medical devices revenue in the first quarter of 2026 grew about 8.5% year over year, driven largely by strength in electrophysiology, rhythm management and heart failure products, suggesting continued momentum in procedure-dependent categories.Zacks as of 04/17/2026

Abbott’s diagnostics business supplies laboratory instruments, assays and point-of-care tests that help detect diseases and monitor chronic conditions, and the recently completed Exact Sciences transaction is expected to add cancer-focused diagnostics to this existing portfolio.

Through its nutrition segment, Abbott sells infant formula, pediatric nutrition products and adult nutrition brands, which provide stable, consumer-oriented revenue streams but also expose the company to regulatory oversight, particularly in markets such as the United States where safety standards are tightly enforced.

The established pharmaceuticals business focuses on branded generics in emerging markets, with a portfolio that includes treatments for cardiovascular, metabolic and gastrointestinal conditions, which can benefit from demographic trends and rising access to healthcare in developing economies.

Abbott’s business model combines high-technology medical devices with consumable test kits, nutrition products and generic medicines, creating a blend of growth-oriented and cash-generative segments that can help balance cyclical swings in any individual category.

Main revenue and product drivers for Abbott Laboratories

First-quarter 2026 results highlighted that medical devices are currently one of Abbott’s most dynamic growth drivers, with Zacks pointing to strong demand in electrophysiology and rhythm management as procedure volumes have normalized or grown after earlier pandemic-related disruptions.Zacks as of 04/17/2026

Cardiovascular and heart failure devices help address chronic conditions, supporting recurring revenue as physicians adopt new technologies and patients require ongoing management, which can be attractive for investors watching long-term device replacement and upgrade cycles.

The diagnostics unit, now augmented by the acquisition of cancer diagnostics assets from Exact Sciences, is another key driver, as oncology testing demand is expected to expand with screening programs and personalized medicine initiatives in the United States and other developed markets.

While COVID-19 testing revenue has declined from the peak pandemic years, core laboratory systems, immunoassays and point-of-care testing are central to ongoing hospital and outpatient workflows, providing a base of recurring consumables revenue tied to installed instruments.

In nutrition, products for infants, children and adults continue to be material contributors to Abbott’s top line, with recognized brands providing pricing power, although the infant formula subsegment is under scrutiny due to litigation and regulatory developments described by Simply Wall St.Simply Wall St as of 05/10/2026

Established pharmaceuticals in emerging markets offer exposure to growing healthcare spending in regions such as Latin America and parts of Asia, where Abbott sells branded generics that leverage its manufacturing and distribution capabilities to address local therapeutic needs.

Across all segments, Abbott’s revenue mix combines device hardware with recurring consumables such as test cartridges and nutritional products, which can smooth revenue patterns and support cash flow generation that helps fund research, development and shareholder distributions.

Why Abbott Laboratories matters for US investors

For US investors, Abbott is a large-cap healthcare name listed on the New York Stock Exchange, and its operations are deeply linked to trends in US hospital spending, insurance coverage, and consumer demand for medical devices and nutrition products.

The company’s presence in cardiovascular devices, diagnostics and diabetes care aligns it with key segments of the US healthcare system where aging demographics and the prevalence of chronic disease support ongoing demand for treatment and monitoring solutions.

At the same time, Abbott’s infant formula and nutrition operations in the United States attract regulatory attention and litigation risk, as reflected in the securities lawsuit coverage by Simply Wall St, meaning US investors may weigh potential legal costs and reputational impact alongside the company’s growth and income profile.Simply Wall St as of 05/10/2026

Conclusion

Abbott Laboratories enters the remainder of 2026 with solid first-quarter growth, increased earnings guidance and a continued dividend, while also managing legal challenges and share price volatility. The company’s diversified portfolio across medical devices, diagnostics, nutrition and generics offers multiple revenue streams, including exposure to long-term themes such as cardiovascular care and oncology testing. For US investors, the stock represents a significant healthcare name where fundamental performance and cash returns must be weighed against regulatory and litigation risks in segments like infant formula, as well as broader market sentiment toward large-cap health stocks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.